---
source_url: https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/acute_bronchitis
content_type: therapeutic_choices
document_id: acute_bronchitis
source_system: CPS (Canadian Pharmacists Association)
processed_at: '2025-05-29T07:19:40.651428Z'
processing_stage: url_preservation_final
pipeline_version: '1.0'
download_date: unknown
converted_from: acute_bronchitis.html
redownload_instructions:
  method: Use unified downloader
  command: python cps_unified_downloader.py --types therapeutic_choices
  note: Requires valid CPS access credentials
---

# Acute Bronchitis

### Acute Bronchitis

|  |
| --- |
| Cindy Marshall, MD, CCFP, FCFP |
| Date of Revision: February 12, 2025 |
| Peer Review Date: April 24, 2024 |


#### Introduction

Cough is one of the most common presenting symptoms in primary care practice. Acute bronchitis is a condition characterized by the acute onset of cough (with or without sputum production) that is present for <3 weeks.‚Äã[^[1]]‚Äã[^[2]] Acute bronchitis is a transient inflammation of the trachea and major bronchi‚Äã[^[3]] and should be differentiated from viral rhinitis (the common cold), acute exacerbation of COPD, asthma and community-acquired pneumonia.‚Äã[^[4]] Viral infection is present in >90% of uncomplicated acute bronchitis;‚Äã[^[5]] see Table 1 for more information regarding etiology.‚Äã[^[4]]‚Äã[^[6]]‚Äã[^[7]]‚Äã[^[8]]‚Äã[^[9]]‚Äã[^[10]]

 Acute bronchitis is generally self-limited and symptoms usually resolve in a median of 18 days,‚Äã[^[11]] but cough can last for up to 8 weeks.‚Äã[^[1]]‚Äã[^[12]] For cough lasting >8 weeks, see Chronic Cough in Adults.

| Etiology of Bronchitis | Frequency of Causation | Comments |
| --- | --- | --- |
| Viral | >90% | Most common viral isolates in acute bronchitis based on age (in order of prevalence):<1 y: RSV, parainfluenza, coronavirus (including SARS-CoV-2)1‚Äì10 y: parainfluenza, enterovirus, RSV>10 y: influenza, parainfluenza, RSV, rhinovirus; less commonly adenovirus, coronavirus (including SARS-CoV-2), enterovirus |
| Bacterial | 5‚Äì10% | The only isolates shown to cause acute bacterial bronchitis are Chlamydophila pneumoniae, Mycoplasma pneumoniae, Bordetella pertussis and B. parapertussisThere is no evidence that Streptococcus pneumoniae, Haemophilus influenzae or Moraxella catarrhalis cause acute bronchitis in adults in the absence of underlying lung disease. There is a lack of strong evidence to support the concept of ‚Äúacute bacterial bronchitis‚Äù |
| Noninfectious | Not well studied | Includes chemical and fume inhalational exposures, e.g., tobacco, other pulmonary irritants |


respiratory syncytial virus

severe acute respiratory syndrome coronavirus 2

#### Goals of Therapy



#### Investigations

For the recommended approach to a patient presenting with acute cough (<3 wk), see Figure 1.



#### Therapeutic Choices

See Figure 1 for the recommended management of acute bronchitis.

#### Nonpharmacologic Choices

The nonpharmacologic approach is the mainstay of management:



#### Pharmacologic Choices

No routine pharmacologic treatment is advocated in the management of acute bronchitis.‚Äã[^[4]] Therapeutic options for symptomatic management of acute bronchitis are presented in Table 3.

#### Antipyretics and Analgesics

Antipyretics or analgesics, such as acetaminophen or ibuprofen, may be used for symptomatic relief of fever, headache, myalgias or chest discomfort.‚Äã[^[1]] The use of NSAIDs in patients with uncomplicated acute bronchitis has not been shown to reduce the severity or duration of cough.‚Äã[^[23]] 

In children, recommend NSAIDs or acetaminophen only in the presence of fever.‚Äã[^[10]]

#### Antihistamines

Antihistamines have been found to be no more effective than placebo in reducing mean cough scores in adults who do not smoke or children with acute bronchitis, and have increased adverse effects.‚Äã[^[24]]‚Äã[^[25]]

#### Antitussives and Nonprescription Cough and Cold Products

Mucolytic and expectorant preparations have failed to show any significant benefit in the management of acute bronchitis.‚Äã[^[4]] A Cochrane review concluded there is no good evidence for the use of nonprescription medications in the treatment of acute cough in adults and children, as the studies are of varying quality with conflicting results;‚Äã[^[26]] higher-quality studies are required.

In adults and children with acute cough, codeine was no more effective than placebo in reducing cough symptoms.‚Äã[^[25]] Health Canada recommends against the use of opioid-containing cough and cold products (e.g., codeine, hydrocodone) in patients <18 years of age.‚Äã[^[27]]

#### Bronchodilators

Short-acting beta2-agonists (SABAs), e.g., salbutamol, terbutaline, are not recommended for routine use in acute bronchitis as they may cause adverse effects such as tremor and nervousness (number needed to harm [NNH] =2 patients).‚Äã[^[28]] However, in patients experiencing bronchial hyper-responsiveness, wheeze or FEV1 <80% of predicted values, they may reduce cough.‚Äã[^[29]]

Studies in the pediatric population did not demonstrate any improvement in cough; however, trials excluded children with airflow obstruction.‚Äã[^[29]]

#### Corticosteroids

There is no available evidence to support the use of inhaled or oral corticosteroids in the management of acute bronchitis.‚Äã[^[5]]‚Äã[^[30]] Furthermore, there is evidence against oral steroid use in patients with acute bronchitis.‚Äã[^[31]]

#### Antibiotics

Routine antibiotic treatment in uncomplicated acute bronchitis is not recommended,‚Äã[^[2]]‚Äã[^[5]]‚Äã[^[25]]‚Äã[^[32]]‚Äã[^[33]] since the etiology is viral in over 90% of cases. Antibiotic treatment does not have a consistent impact on the severity of illness, the clinical condition, or the prevention of potential complications, e.g., pneumonia.‚Äã[^[8]]‚Äã[^[32]] A Cochrane systematic review assessed 17 trials involving almost 5100 patients; overall, patients taking antibiotics showed only a modest benefit, if any, compared with placebo. Evidence suggests antibiotics may reduce the duration of cough by half a day; however, this marginal benefit for the treatment of a self-limited illness is offset by the potential for adverse reactions to antibiotics and an increase in antibiotic resistance (NNH = 24).‚Äã[^[32]]

In an otherwise healthy patient who is clinically stable and with no apparent signs of bacterial pneumonia, the use of antibiotics is not recommended, even when a bacterial cause is suspected.‚Äã[^[32]]‚Äã[^[34]] There is no evidence that people who smoke but do not have lung disease are more likely to benefit from antibiotics than those who do not smoke.‚Äã[^[24]] Of note, prescribing antibiotics raises the likelihood of patients and their family members receiving additional antibiotics for future acute respiratory illnesses.‚Äã[^[35]]

See Table 2 for tips on talking to patients who want antibiotics for acute bronchitis.

|  |
| --- |
| Bronchitis is usually caused by a virus. Antibiotics do not kill viruses; they kill bacteria. Therefore, antibiotics will not reduce your symptoms of cough, phlegm or feeling unwell.Taking an antibiotic for your bronchitis will not prevent you from developing secondary infections such as pneumonia or sinusitis.Taking antibiotics too often or when you don‚Äôt need them can be harmful in several ways:side effects occur in 5‚Äì25% of people who take antibiotics (nausea, vomiting, vaginitis, oral thrush, Clostridioides difficile, allergic reactions); 1:1000 will have a serious side effect (e.g., allergic reaction)there is a cost to the health-care system of unnecessary treatmentthe antibiotic may not work the next time you need it; this is called antibiotic resistanceBronchitis is a chest cold that will take 2‚Äì3 weeks to resolve on its own. Measures you can take to help clear it include:Getting enough rest so your body can fight the virusRelieving your cough by drinking fluids, increasing humidity, using cough drops and avoiding things like smoke, which irritates your lungsUsing nonprescription medications to reduce fever, nasal congestion and body achesProtecting others by washing your hands frequently and covering your mouth when you cough |


#### Natural Health Products

A Cochrane review found honey to be more effective than diphenhydramine, salbutamol and placebo, but no better than dextromethorphan, in improving cough frequency and severity in both adults and children.‚Äã[^[37]] Due to the risk of botulism, honey should be pasteurized and given only to immunocompetent children >1 year of age.

*Pelargonium sidoides* (umckaloabo, South African geranium) is an herbal remedy that, according to some low-quality RCTs, may be effective in relieving symptoms in acute bronchitis.‚Äã[^[38]] The preparation appears to be generally well tolerated, although allergic skin reactions, GI upset and liver toxicity have been reported. Recent studies suggest safety and effectiveness in the pediatric population, but current evidence is insufficient to recommend routine use.‚Äã[^[39]]‚Äã[^[40]] 

There is some evidence that **North American** ginseng extract taken prophylactically may reduce the duration of the common cold (see Viral Rhinitis).‚Äã[^[41]] No studies have evaluated the effect of the extract on acute bronchitis.

Studies are ongoing with respect to Tropaeolum majus, a herb postulated to reduce symptoms in acute bronchitis.

There is insufficient evidence to recommend Chinese medicinal herbs for the treatment of acute bronchitis.‚Äã[^[3]]‚Äã[^[42]]

#### Choices during Pregnancy and Breastfeeding

During pregnancy and breastfeeding, symptomatic management of acute bronchitis can be achieved via supportive measures similar to those used in the nonpregnant patient (see Nonpharmacologic Choices). Fever, headache and discomfort can be managed safely with acetaminophen.‚Äã[^[43]] NSAIDs are not recommended in late pregnancy due to the risk of premature closure of the ductus arteriosus;‚Äã[^[44]] they are also not recommended after 20 weeks‚Äô gestation due to a potential reduction in amniotic fluid.‚Äã[^[45]] If needed, cough may be controlled with dextromethorphan‚Äã[^[46]]‚Äã[^[47]] or opioids; however, opioids should be used cautiously near term. Health Canada and the United States FDA advise against the use of¬†codeine¬†during breastfeeding unless the benefits outweigh the risks (CNS and respiratory depression in the infant).‚Äã[^[48]]‚Äã[^[49]] Controversy exists in the interpretation of the case report that was one of the bases for this recommendation;‚Äã[^[50]]‚Äã[^[51]] until the controversy is resolved, it is reasonable to limit use of codeine in breastfeeding patients (for more information, see Drug Use during Breastfeeding). Inhaled **short-acting** beta2-adrenergic agonists (SABAs) are considered safe during pregnancy and breastfeeding but side effects need to be weighed against minimal symptomatic benefit.‚Äã[^[52]]

A discussion of general principles on the use of medications in these special populations can be found in Drugs Use during Pregnancy and Drug Use during Breastfeeding. Other specialized reference sources are also provided in these appendices.

#### Therapeutic Tips



#### Algorithms

![](images/acutebronchitis_manacubro.gif)


**AI Image Description:**
The image is a medical flowchart for evaluating acute onset cough lasting less than three weeks, with or without sputum. Here is a detailed description of its contents:

1. **Initial Condition:**
   - Acute onset cough lasting less than 3 weeks, with or without sputum.

2. **First Decision Point:**
   - Rule out other causes of acute cough, such as:
     - GERD (Gastroesophageal Reflux Disease)
     - COVID-19
     - Heart failure
     - PE (Pulmonary Embolism)
     - ACE inhibitor ADR (Adverse Drug Reaction)

3. **Second Decision Point:**
   - Check for signs of:
     - Fever
     - Increased respiratory rate
     - Tachycardia
     - Consolidation
     - Airway obstruction
   - **If Yes:** Consider pneumonia, asthma, or other pulmonary diseases.
   - **If No:** Proceed to the next decision point.

4. **Third Decision Point:**
   - Determine if there is a documented outbreak of influenza or pertussis.
   - **If Yes:** Treat as appropriate.
   - **If No:** Diagnose as acute bronchitis.

5. **Management of Acute Bronchitis:**
   - Establish expectation of up to a 21-day duration of cough (though 50% will persist for up to 8 weeks).
   - Educate regarding viral causes being most common and the lack of evidence for antibiotics.
   - Encourage adequate fluid intake and increased humidity.
   - No routine treatment recommended; options for symptom management are listed in Table 3.
   - Educate regarding the need to be reassessed if symptoms worsen, presence of fever, etc.

This flowchart provides a structured approach to diagnosing and managing acute onset cough, emphasizing the importance of ruling out other causes and managing symptoms appropriately.

*AI-generated description for accessibility and content understanding*


angiotensin-converting enzyme

adverse drug reaction

gastroesophageal reflux disease

pulmonary embolism

#### Drug Table


**Drug Class: Analgesics/Antipyretics**


**Drug Class: Antitussives**


**Drug Class: Beta2-Adrenergic Agonists, short-acting**

| Drug/‚ÄãCost[a] | Dosage | Adverse Effects | Drug Interactions | Comments |
| --- | --- | --- | --- | --- |
| **acetaminophen** (Tempra, Tylenol, generics) | Adults and children >12 y: 325‚Äì650 mg Q4‚Äì6H PRN PO; maximum 4 g/dayChildren: 10‚Äì15 mg/kg Q4‚Äì6H PRN PO; maximum 5 doses/day or 75 mg/kg/day or adult dose, whichever is less | Well tolerated; GI upset (rare), less than salicylates. | May enhance anticoagulant effect of warfarin, particularly with doses of >1.3 g/day for >1 wk. | Use with caution in patients with hepatic impairment. Severe hepatic damage can occur with overdose. |
| **ibuprofen** (Advil, Advil, Motrin, Motrin, generics) | Adults: 200‚Äì400 mg TID‚ÄìQID PRN PO; maximum 2.4 g/dayChildren: 5‚Äì10 mg/kg Q6‚Äì8H PRN PO; maximum 40 mg/kg/day or adult dose, whichever is less | Primarily GI (nausea, epigastric pain, heartburn).Possibility of increased blood pressure or GI bleed. | ASA/anticoagulants may increase risk of bleeding. | Contraindicated in patients with active peptic ulcer disease or inflammatory bowel disease. Contraindicated in patients who have a history of or are at risk of ASA/NSAID intolerance (asthma, anaphylaxis, urticaria, angioedema, rhinitis).Caution in patients with decreased renal function, especially if taking diuretic and/or ACE inhibitor.Caution in patients with cardiac risk factors and those with uncontrolled blood pressure.In children, should only be used in the presence of fever. |
| **codeine (many products contain additional ingredients)** (generics) | Immediate-release:Adults: 10‚Äì20 mg Q4‚Äì6H PRN PO; maximum 120 mg/dayChildren <18 y: Health Canada recommends against the use of opioid-containing cough and cold products (e.g., codeine, hydrocodone) in children and youth‚Äã[27] | Sedation, nausea/vomiting, constipation. | Additive sedation with other CNS depressants; use with caution.Inhibitors of CYP2D6 (e.g., amiodarone, cimetidine, fluoxetine, moclobemide, paroxetine, quinidine) may antagonize codeine's effect. | Use with caution in pregnant, older or debilitated patients.Avoid in breastfeeding patients because of the risk of toxicity in the infant.‚Äã[48]‚Äã[49]There is paucity of evidence for the use of codeine in acute bronchitis. Opioids (e.g., codeine, hydrocodone) are associated with increased adverse effects compared with other antitussives.Genetic polymorphisms cause some individuals to more rapidly metabolize codeine to its active form (morphine), resulting in potentially toxic levels. Conversely, others may not produce enough morphine for efficacy. |
| **dextromethorphan** (Benylin, Robitussin, generics) | Adults and children >12 y: 30 mg Q6‚Äì8H PRN PO; maximum 120 mg/dayChildren 6‚Äì12 y: 15 mg Q6‚Äì8H PO; maximum 60 mg/dayFor combination products: consult label for additional ingredients; follow dosing directions on label | Rare but can cause nausea, drowsiness, dizziness. | Caution with CNS depressants (can potentiate effects).Do not use with MAOI or for 2 wk after stopping MAOI.SSRIs may enhance adverse effects of dextromethorphan. | Not recommended in patients with asthma or children <6 y. |
| **hydrocodone** (generics) | Adults: 5 mg Q4‚Äì6H PRN PO; may increase to 10 mg/dose; maximum 30 mg/dayChildren <18 y: Health Canada recommends against the use of opioid-containing cough and cold products (e.g., codeine, hydrocodone) in children and youth‚Äã[27] | Lightheadedness, dizziness, sedation, nausea and vomiting, constipation. | Additive sedation and risk of respiratory depression with other CNS depressants; use with caution. | Use with caution in pregnant, older or debilitated patients.Avoid in breastfeeding patients because of risk of toxicity in the infant.Opioids (e.g., codeine, hydrocodone) are associated with increased adverse effects compared with other antitussives. |
| **salbutamol** (Ventolin, Ventolin, generics) | Diskus (200 mcg/inhalation): Adults and children ‚â•4 y: 1 inhalation TID‚ÄìQID PRN; maximum 800 mcg/dayMDI: Adults and children ‚â•4 y: 1‚Äì2 puffs (100‚Äì200 mcg) QID PRNMaximum (adults and children ‚â•12 y): 800 mcg/dayMaximum (children <12 y): 400 mcg/day | Tremor, restlessness, palpitations, dizziness, headache, nausea, hypokalemia, tachycardia. | Caution with other sympathomimetic agents. | Contraindicated in patients with arrhythmias or hypertrophic obstructive cardiomyopathy.No evidence for use in acute bronchitis unless airflow obstruction is present.Caution with ischemic heart disease, vascular disease and hypertension. |
| **terbutaline** (Bricanyl) | Adults and children ‚â•6 y: 1 inhalation (0.5 mg/inhalation) QID PRN; maximum 6 inhalations/day | Tremor, restlessness, palpitations, dizziness, headache, nausea, hypokalemia, tachycardia. | Caution with other sympathomimetic agents. | Contraindicated in patients with arrhythmias or hypertrophic obstructive cardiomyopathy.No evidence for use in acute bronchitis unless airflow obstruction is present.Caution with ischemic heart disease, vascular disease and hypertension. |


**ü´ò Renal Monitoring - Monitor kidney function when using this medication**

<!-- AI description pending for: images/kidney.gif -->

angiotensin-converting enzyme

acetylsalicylic acid

central nervous system

cytochrome P450

gastrointestinal

monoamine oxidase inhibitor

metered dose inhaler

nonsteroidal anti-inflammatory drug

selective serotonin reuptake inhibitor

#### Suggested Readings

Kinkade S, Long NA. Acute bronchitis. *Am Fam Physician* 2016:94(7):560-5.

Kolinsky DC, Schwarz ES. Do Œ≤-2 agonists for acute bronchitis provide any benefit? *Ann Emerg Med* 2016;67(6):702-3.

Michigan Quality Improvement Consortium. (May 2022). *Management of uncomplicated acute bronchitis in adults* [PDF file]. Available from: mqicmanagementofuncomplicatedacutebronchitisinadultsFINAL2022.pdf.

Smith MP, Lown M, Singh S et al. Acute cough due to acute bronchitis in immunocompetent adult outpatients: CHEST Expert Panel report. *Chest* 2020;157(5):1256-65.

Wenzel RP, Fowler AA. Clinical practice: acute bronchitis. *N Engl J Med* 2006;355(20):2125-30.

Worrall G. Acute cough in adults. *Can Fam Physician* 2011;57(1):48-51.

#### References


---

## Source Information

**Original Source:** [https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/acute_bronchitis](https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/acute_bronchitis)  
**Content Type:** therapeutic_choices  
**Processed:** 2025-05-29 07:19 UTC  
**Source System:** Canadian Pharmacists Association (CPS)

### How to Cite
> Canadian Pharmacists Association. *acute_bronchitis*. 
> CPS Online. Retrieved 2025-05-29 07:19 UTC from https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/acute_bronchitis


```

*Note: This document was processed using automated tools. Always refer to the original source for the most up-to-date information.*

---
*Document processed with CPS Pipeline v1.0 ‚Ä¢ [Source URL](https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/acute_bronchitis)*
